Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Atavistik launches for allosteric drug discovery

by Ryan Cross
August 30, 2021 | A version of this story appeared in Volume 99, Issue 31

 

Atavistik Bio has launched with $60 million in series A financing to develop small-molecule drugs for metabolic diseases and cancer. The start-up is based on the work of Jared Rutter, a biochemist at the University of Utah who studies how metabolites act as allosteric regulators of proteins. His research has led to new strategies for targeting proteins implicated in disease. The firm’s acting CEO is John A. Josey, former CEO of Peloton Therapeutics, which Merck & Co. acquired in 2019.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.